Introduction: Myrrh has been used traditionally for the inhibition of microbial growth and for the treatment of rheumatic diseases. Despite this, myrrh extracts are yet to be tested for the ability to inhibit the growth of the bacterial triggers of autoimmune inflammatory diseases. Methods: Solvent extracts prepared from commercially obtained myrrh resin were analysed for the ability to inhibit the growth of bacterial species associated with initiating rheumatoid arthritis (P. mirabilis), ankylosing spondylitis (K. pneumoniae) and multiple sclerosis (A. baylyi, P. aeruginosa) by disc diffusion assay, and quantified by MIC determination. Toxicity was determined by Artemia franciscana bioassay. The most potent inhibitory extract was investigated using non-targeted GC-MS head space analysis (with screening against a compound database) for the identification and characterisation of individual components in the crude plant extracts. Results: Methanolic myrrh extract inhibited the growth of all bacterial species tested. The growth inhibition of this extract was particularly notable against P. mirabilis and K. pneumoniae, with MIC values substantially < 1000 µg/mL for both reference and clinical bacterial strains. Indeed, the MIC values of the methanolic extract against P. mirabilis reference and clinical strains were 572 and 463 µg/mL respectively. The methanolic extract also inhibited the growth of A. baylyi (MIC approximately 3000 µg/mL) and P. aeruginosa (MIC approximately 1800 µg/mL). However, the MICs against these bacteria was indicative of only moderate inhibitory activity. The aqueous, ethyl acetate,